Clin2
NCT07805252Possibly a fitRecruiting

A new drug for advanced cancer that has stopped responding to treatment

Advanced Solid Tumors Cancer

This trial tests a new drug called ODM-216 in people with advanced cancer that has not responded to standard treatments. The drug is given as a pill (likely), and the study will see how it affects the cancer and what side effects it causes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
195 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You need to have a cancer that is advanced (has spread) and you have already tried standard treatments that either didn't work or caused too many side effects.
  • You must be able to do your daily activities with little or no help (a score of 0 or 1 on a standard activity scale).
  • You must agree to have a biopsy (a small sample of your tumor taken) before starting the trial.
  • You cannot have had certain cancer treatments (like chemo, targeted therapy, immunotherapy, or radiation) in the last 3 to 4 weeks.
  • You must not have an autoimmune disease that required treatment in the past 2 years, unless it is mild.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06898450Recruiting· Phase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors

This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.

Los Angeles, California
NCT07563738Recruiting· Phase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors

This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.

Irving, Texas
NCT06725758Recruiting· Phase 1/Phase 2
First-in-human study of ODM-212 for advanced solid tumors

This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).

Los Angeles, California
NCT06998173Not yet recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.

Beijing, Beijing Municipality
NCT06923761Recruiting· Phase 1/Phase 2
Trial of a new drug for advanced solid tumors

This trial tests a new drug (GRWD5769) that may help your immune system fight cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including certain types of cervical, liver, and other cancers.

Adelaide
NCT07377591Recruiting· Phase 1
Study of HDM2006 for advanced solid tumors

This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.

Shanghai

Hear when a new Advanced Solid Tumors Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.